Bristol Myers Squibb (BMS) reports that the company is investing $400 million in its Dublin 15 Cruiserath Campus (BMS Cruiserath Biologics) to fund the build and design of a sterile drug product (SDP) facility which will support the manufacturing and supply of existing medicines as well as serve as a launch excellence facility for pipeline assets.

The investment decision represents BMS’ first European SDP facility for biologics manufacturing and is currently in the design phase, according to a company spokesperson, who adds that construction is expected to begin next month now that planning approval has been received, for completion in 2026. The company’s commercial and pipeline portfolio includes a range of therapeutic areas such as oncology, immunology, and hematology.

Adding to the existing biologic manufacturing operations for bulk drug substance, this new investment is expected to significantly expand manufacturing and laboratory capacity in Cruiserath, as the campus adds new technologies and capabilities supporting SDP manufacturing, explains Padraig Keane, VP, Cruiserath Biologics. The co-location of drug substance and drug product manufacturing alongside existing global testing capabilities offers significant strategic agility to the global supply of medicinal products to patients from our commercial brands and clinical pipeline, he points out.

“This investment will expand our capacity for aseptic drug products, reinforce stable production for global supply, and accelerate the development and commercialization of innovative biologic therapies alongside other pipeline medicines,” continues Keane. “This year we celebrate 60 years of BMS in Ireland, across our three sites in Ireland we continue to play a critical role in the global production, development, and supply network.

Previous articleNovel Autoimmune Disease Trigger Uncovered
Next articleIn a First, Organoid Model Resembles All Three Sections of Embryonic Brain and Spinal Cord